Physician profile
Thida Win
NPI 1871754507
$5,113.85
in general payments reported to CMS, 2019-2025
16 companies · $603 in 2025
The $603 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,378 · 2020: $379 · 2021: $477 · 2022: $1,138 · 2023: $482 · 2024: $657 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,741.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,687.44 | 2021-2025 | Avycaz |
| Merck Sharp & Dohme LLC | $960.99 | 2019-2025 | Recarbrio, Zerbaxa, Dificid |
| Allergan, INC. | $743.75 | 2019-2020 | |
| Amgen INC. | $506.22 | 2019-2022 | |
| Shionogi INC | $305.18 | 2022-2025 | Fetroja |
| Astrazeneca Pharmaceuticals Lp | $250.00 | 2021-2025 | Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $219.13 | 2022-2025 | |
| Akebia Therapeutics INC | $131.67 | 2023-2025 | Auryxia, Vafseo |
| Calliditas Therapeutics US INC. | $63.07 | 2023-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.59 | 2024 | Jardiance |
| Opko Pharmaceuticals, LLC | $48.86 | 2022-2024 | Rayaldee |
| Aurinia Pharma U.S., INC. | $36.89 | 2022-2023 | Lupkynis |
| Lilly USA, LLC | $35.52 | 2024 | Jardiance |
| Ardelyx, INC. | $24.50 | 2025 | Ibsrela |
| Travere Therapeutics, INC. | $24.33 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $20.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thida Win listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.